Sort
10,766 grants matching “checkpoint inhibitor”
T cell-intrinsic metabolic control of radiotherapy
$419,461Lewis Zhichang Shi · University Of Alabama At Birmingham · R01 · FY2024 · CA
T cell-intrinsic metabolic control of radiotherapy
$419,461Lewis Zhichang Shi · University Of Alabama At Birmingham · R01 · FY2025 · CA
Studies of the DNA replication checkpoint
$419,400Paul R Russell · Scripps Research Institute, The · R01 · FY2007 · GM
Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome
$419,283Lajos Pusztai · Yale University · R01 · FY2018 · CA
Using dietary glutamine supplementation for melanoma prevention and targeted therapy
$419,220Mei Kong · University Of California-Irvine · R01 · FY2022 · CA
Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma
$419,207Yibin Yang · Research Inst Of Fox Chase Can Ctr · R01 · FY2023 · CA
Targeting mechanisms of immune evasion in chemotherapy-induced senescent cells
$419,189James Jackson · Tulane University Of Louisiana · R01 · FY2023 · CA
Developmental Funds
$419,048Helen E Heslop · Baylor College Of Medicine · P30 · FY2022 · CA
Developmental Funds
$419,048C Kent Osborne · Baylor College Of Medicine · P30 · FY2020 · CA
Developmental Funds
$419,048Helen E Heslop · Baylor College Of Medicine · P30 · FY2023 · CA
Developmental Funds
$419,048Helen E Heslop · Baylor College Of Medicine · P30 · FY2024 · CA
Impact of senescence on T-cell function and immunotherapeutic response
$418,905Christin E Burd · Ohio State University · R01 · FY2018 · AG
Impact of senescence on T-cell function and immunotherapeutic response
$418,905Christin E Burd · Ohio State University · R01 · FY2019 · AG
Elucidating genetics of response to immune checkpoint blockade in lung cancer
$418,751Timothy An-Thy Chan · Cleveland Clinic Lerner Com-Cwru · R01 · FY2021 · CA
Toward understanding the role of altered glycosylation in cancer
$418,750Stacy Alyse Malaker · Yale University · R35 · FY2025 · GM
Toward understanding the role of altered glycosylation in cancer
$418,750Stacy Alyse Malaker · Yale University · R35 · FY2023 · GM
Toward understanding the role of altered glycosylation in cancer
$418,750Stacy Alyse Malaker · Yale University · R35 · FY2024 · GM
Targeting immune suppressive microenvironment in ATC
$418,682James A Fagin · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C
$418,592Neal Rosen · Sloan-Kettering Inst Can Research · P50 · FY2008 · CA
Platelets-Mediated Delivery of Checkpoint Inhibitors for Post-Surgical Cancer Immunotherapy
$418,528Zhen Gu · University Of California Los Angeles · R01 · FY2019 · CA
Linking Epigenetic-Therapy Induction of Inflammasome Signaling to Generation of a BRCAness Phenotype
$418,484Kenneth P Nephew · Coriell Institute For Medical Research · P50 · FY2025 · CA
Tumor Suppressor Protein, p53
$418,446Ettore Appella · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
CD206 activators as novel immunomodulators
$418,442Juan Marugan · National Center For Advancing Translational Sciences · ZIA · FY2025 · TR
Cellular and molecular regulators of melanocyte regeneration
$418,399Craig Joseph Ceol · Univ Of Massachusetts Med Sch Worcester · R01 · FY2025 · AR
Protective Role of Nonclassical Monocytes in Immunotherapies for Solid Cancers
$418,320Catherine C Hedrick · La Jolla Institute For Immunology · U01 · FY2018 · CA